2020 CMO Scorecard: CMO Industry Performance and Relative Performance of Major CMOs

DUBLIN, June 9, 2020 /PRNewswire/ -- The "CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2020 Edition" report has been added to ResearchAndMarkets.com's offering.


This report is the 10th edition of the long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.

Key report benefits:

    --  Overview of NDA drug approvals and the levels of outsourcing associated
        with NDA sub segments
    --  Detailed view of CDMO performance by number of approvals and an
        assessment of their sponsors market caps from the Contract Service
        Providers database
    --  Outsourcing propensity for NMEs, different dosage forms and by sponsor
        company cap have all been assessed.
    --  Analysis of NME special products approvals such as those with Orphan,
        Breakthrough or Fast Track designations and assessment of outsourcing

This report is required reading for -

    --  CMO executives who must have deep understanding of the injectables
        marketplace to make strategic planning and investment decisions.
    --  Sourcing and procurement executives who must understand crucial
        components of the supply base in order to make decisions about supplier
        selection and management.
    --  Private equity investors that need a deeper understanding of the market
        to identify and value potential investment targets.

Key Topics Covered:

1 Table of Contents

2 List of Tables

3 List of Figures

4 Executive Summary

5 Introduction

6 FDA NDA Approvals Overview

7 US vs. EU Approval Performance

8 FDA: Outsourced Dose Manufacture

9 Special Product Categories

10 Outsourcing by Company Market Cap

11 CMO Performance
11.1 Catalent
11.2 Patheon
11.3 Other Prominent CMOs

12 Outsourced API Approvals

13 What It Means
13.1 FDA Approvals Have Fallen but Are Still Strong Compared to Historical Standards
13.2 Drivers and Barriers for Outsourcing
13.2.1 Niche Technology
13.2.2 Small Volumes, Special Designations
13.2.3 Sponsor Market Cap Relationships to Outsourcing

14 Notes on Methodology

15 Appendix

Companies Mentioned

    --  Patheon NV
    --  Catalent Inc
    --  Vetter Pharma-Fertigung GmbH & Co KG
    --  PCI Pharma Services
    --  Baxter International Inc
    --  Mylan NV
    --  Pfizer Inc
    --  Almac Group Ltd
    --  Siegfried Holding AG
    --  Ajinomoto Co Inc
    --  Emergent BioSolutions Inc
    --  Fareva SA
    --  Aenova Holding GmbH
    --  Alcami Corp
    --  Renaissance Pharma Inc
    --  Albany Molecular Research Inc
    --  Fujifilm Corp
    --  Jubilant Life Sciences Ltd
    --  Recipharm AB
    --  Boehringer Ingelheim International GmbH
    --  Cenexi SAS
    --  Delpharm SAS
    --  Rottendorf Pharma GmbH
    --  ACS Dobfar SpA
    --  Fresenius Kabi AG
    --  Hovione FarmaCiencia SA
    --  Lonza Group Ltd
    --  Gland Pharma Ltd
    --  Takeda Pharmaceutical Co Ltd
    --  Quotient Sciences Ltd
    --  3M Drug Delivery Systems
    --  Afton Scientific Corp
    --  Cadila Healthcare Ltd
    --  Cipla Ltd
    --  Consort Medical Plc
    --  Rentschler Biopharma SE
    --  Johnson & Johnson
    --  LTS Lohmann Therapie-Systeme AG
    --  Merck & Co Inc
    --  Mikart Inc
    --  Cambrex Corp
    --  Piramal Enterprises Ltd
    --  Sanofi
    --  Unither Pharmaceuticals
    --  Adoh BV
    --  ARx LLC
    --  The Ritedose Corp
    --  Akorn Inc
    --  Alliance Contract Pharma LLC
    --  Alvogen Inc
    --  AstraZeneca Plc
    --  Bausch Health Companies Inc
    --  Bayer AG
    --  Bristol-Myers Squibb Co
    --  Cerovene Inc
    --  Contract Pharmaceuticals Ltd
    --  Galephar Pharmaceutical Research Inc
    --  GlaxoSmithKline Plc
    --  Grunenthal GmbH
    --  Hikma Pharmaceuticals Plc
    --  Instituto Bioclon
    --  Klocke Pharma-Service GmbH
    --  Importfab Inc
    --  MIAS Pharma Ltd
    --  NextPharma Technologies Holding Ltd
    --  Nova Laboratories Ltd
    --  Orion Corp
    --  NMS Group SpA
    --  Perrigo Co Plc
    --  Pharmaceutics International Inc
    --  Sanico NV
    --  Sharp Packaging Services
    --  Alpex Pharma SA
    --  Exelead Inc
    --  Sotera Health LLC
    --  UPM Pharmaceuticals Inc
    --  AbbVie Inc
    --  Groupe Synerlab SAS
    --  3SBio Inc
    --  AlfaSigma SpA
    --  Alkermes Plc
    --  Aquestive Therapeutics Inc
    --  ASM - Aerosol-Service AG
    --  AustarPharma LLC
    --  Avara Pharmaceutical Services Inc
    --  Basic Pharma
    --  Amgen Inc
    --  Sintetica SA
    --  Biogen Inc
    --  BioRamo LLC
    --  BSP Pharmaceuticals SpA
    --  Centre for Probe Development and Commercialization
    --  Therapure Biopharma Inc
    --  Dexcel PT Holdings Ltd
    --  DSM Pharmaceuticals Inc
    --  Ei A Pharmaceutical SolutionWorks (TM)
    --  Eisai Co Ltd
    --  Dongbao Enterprise Group Co Ltd
    --  Exela Pharma Sciences LLC
    --  Famar Health Care Services
    --  Ferndale Pharma Group Inc
    --  Fritz Keller Holding AG
    --  Gilead Sciences Inc
    --  GBA Gesellschaft fur Bioanalytik mbh
    --  Glatt GmbH
    --  Glenmark Pharmaceuticals Ltd
    --  Grifols SA
    --  Torii Pharmaceutical Co Ltd
    --  Holopack Verpackungstechnik GmbH
    --  Institutt for Energiteknikk
    --  Insud Pharma
    --  Intas Pharmaceuticals Ltd
    --  James Alexander Corp.
    --  Kyowa Kirin Co Ltd
    --  Lifecore Biomedical LLC
    --  Laboratoires PANPHARMA SA
    --  Laboratoires Pierre Fabre SA
    --  Laboratorios Farmaceuticos Rovi SA
    --  Les Laboratoires Servier SAS
    --  Lyne Laboratories
    --  Molteni Farmaceutici
    --  Merck KGaA
    --  Neolpharma SA De CV
    --  Napp Pharmaceuticals Ltd
    --  Nexgen Pharma Inc
    --  Nordmark Arzneimittel GmbH & Co KG
    --  Novast Holdings Ltd
    --  OishiKoseido Corp
    --  Stada Arzneimittel AG
    --  Nordic Group BV
    --  Novartis AG
    --  Pharmaceutical Manufacturing Research Services Inc
    --  Pharmascience Inc
    --  Pharmasol Corp
    --  Pierrel Spa
    --  Pillar5 Pharma Inc
    --  PARI Pharma GmbH
    --  Porton Biopharma Ltd
    --  Propak Health Ltd
    --  PYRAMID Laboratories Inc
    --  QPS Holdings LLC
    --  R Pharm
    --  Lyophilization Services of New England Inc
    --  Evonik Industries AG
    --  Rivopharm SA
    --  Recro Pharma Inc
    --  Sawai Pharmaceutical Co Ltd
    --  Steri-Pharma LLC
    --  Swedish Orphan Biovitrum AB
    --  Tapemark Co
    --  Teligent Inc
    --  Adare Pharmaceuticals Inc
    --  University of Iowa
    --  Toyobo Co Ltd
    --  Tris Pharma Inc
    --  UCB SA
    --  Vifor Pharma Ltd
    --  USV Pvt Ltd
    --  Vectura Group Plc
    --  Vianex SA
    --  Woodfield Pharmaceutical LLC
    --  WuXi AppTec Co Ltd
    --  Zymeworks Inc

For more information about this report visit https://www.researchandmarkets.com/r/9wfcx5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2020-cmo-scorecard-cmo-industry-performance-and-relative-performance-of-major-cmos-301072741.html

SOURCE Research and Markets